Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical use of hirudo and rhizoma ligustici capsule in treatment of non-alcoholic fatty liver disease

A fatty liver disease, non-alcoholic technology, applied in the application of Zhixiong capsules in the preparation of drugs for the treatment of non-alcoholic fatty liver disease, in the field of compound Chinese patent medicine Zhixiong capsules, can solve non-alcoholic fatty liver disease without Zhixiong capsules, etc. problems, achieve the effect of reducing oxidative stress level, slowing down liver damage, and alleviating liver fat

Active Publication Date: 2020-07-14
SHENYANG PHARMA UNIVERSITY
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The compound Chinese patent medicine Zhixiong Capsule (ZXC) is a mixture of equal amounts of extracts from leeches, Chuanxiong, Pueraria lobata, motherwort and salvia miltiorrhiza. There is no relevant report on Zhixiong Capsules used in the treatment of non-alcoholic fatty liver disease in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of hirudo and rhizoma ligustici capsule in treatment of non-alcoholic fatty liver disease
  • Pharmaceutical use of hirudo and rhizoma ligustici capsule in treatment of non-alcoholic fatty liver disease
  • Pharmaceutical use of hirudo and rhizoma ligustici capsule in treatment of non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Zhixiong Capsule Improves Rat Hepatic Steatosis Caused by High Fat Feed Modeling

[0024] In this embodiment, rats are used as experimental animals, 6 in each group, and are divided into blank group, model group, positive drug group (simvastatin 4.5mg / kg), Zhixiong capsule low-dose group (ZXC-L, 420mg / kg). kg) and high dose group (ZXC-H, 840mg / kg). Rats except the blank group were fed with high-fat diet for 12 weeks. From the 13th week to the 20th week of the experiment, the rats in the positive drug group were given simvastatin once a day, the Zhixiong capsule group was given the Zhixiong capsule aqueous solution, and the blank group and the model group were given the same amount of normal saline. On the last day of the 20th week of the experiment, the rats were sacrificed, and the same area of ​​the liver was taken to be embedded in paraffin, sectioned and stained with oil red. It was found that the administration of Zhixiong Capsules could significantly im...

Embodiment 2

[0025] Example 2 Zhixiong Capsules Reduce Body Weight and Liver Index of NAFLD Model Rats

[0026] Modeling and administration were carried out as described in Example 1, and at the end of the experiment, the body weight of the rats was measured, and then the rats were sacrificed, and the rat liver was obtained, weighed, and the liver index calculated. (Liver index=liver weight / rat body weight*100%) After calculation, it was found that the administration of Zhixiong Capsules could significantly reduce the body weight of rats. Compared with the model group, the administration of Zhixiong Capsules could significantly reduce the liver index of rats.

Embodiment 3

[0027] Example 3 Zhixiong Capsules Reduce Blood Lipid Levels in NAFLD Model Rats

[0028] Modeling and administration as described in Example 1, and at the end of the experiment, measure total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL- C), the levels of high-density lipoprotein cholesterol (HDL-C) and free fatty acids (NEFA), it was found through calculation that the administration of Zhixiong Capsules can significantly reduce the contents of LDL-C, TC, TG and NEFA in rat plasma, Raising the content of HDL-C showed a better effect of lowering blood fat (attached image 3 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of Chinese patent medicines, and relates to pharmaceutical use of a hirudo and rhizoma ligustici capsule in treatment of non-alcoholic fatty liver disease(NAFLD). The hirudo and rhizoma ligustici capsule is prepared from hirudo, rhizoma ligustici, radix puerariae, herba leonuri and radix salviae miltiorrhizae at the ratio of 1 to 1 to 1 to 1 to 1. According to the pharmaceutical use, high fat diet (HFD) induced rat NAFLD model is adopted for studying the treatment effect of ZXC on rat NAFLD, it is found that ZXC can significantly reduce the blood lipid level of the model rat, significantly relieve liver fat caused by HFD, alleviate liver injury, reduce oxidative stress level of liver, and have high medicinal value.

Description

technical field [0001] The invention belongs to the technical field of Chinese patent medicines, and relates to the medical use of compound Chinese patent medicine Zhixiong capsules, in particular to the application of Zhixiong capsules in the preparation of medicines for treating non-alcoholic fatty liver disease. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) is a metabolic stress liver injury, mainly characterized by steatohepatitis, which can lead to symptoms such as cirrhosis and liver cancer. The incidence of NAFLD in the Chinese population is conservatively estimated at 25%. In recent years, it has been found that NAFLD is associated with various complications, such as hyperlipidemia, hypertension, visceral obesity, and cardiovascular diseases. Currently, three drugs are commonly used in NAFLD: (1) drugs to reduce hepatic fat deposition (such as polyene lecithin, ursodeoxycholic acid); (2) antioxidants (such as silyl); (3) to improve insulin re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/537A61P1/16A61K9/48A61K35/62
CPCA61K35/62A61K36/236A61K36/488A61K36/533A61K36/537A61K9/48A61P1/16A61K2300/00
Inventor 殷军翟健秀刘志惠韩娜李嗣凯任兆惠
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com